Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pred Forte in chronic central serous chorioretinopathy
2022-000338-41Phase 3Active
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic central serous chorioretinopathy (CSCR) comparing Pred Forte with Placebo (2 arms). Primary endpoint: Primary anatomical endpoint on OCT. Started Mar 2022; status: active.
02
Drugs
prednisolone
03
Conditions
Chronic central serous chorioretinopathy (CSCR)
Beyond the preview
Go deeper on 2022-000338-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000338-41.